搜索结果：PM & R : the journal of injury, function, and rehabilitation

BACKGROUND: The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 comparative risk assessment (CRA) is a comprehensive approach to risk factor quantification that offers a useful tool for synthesising evidence on risks and risk-outcome associations. With each annual GBD study, we update the GBD CRA to incorporate improved methods, new risks and risk-outcome pairs, and new data on risk exposure levels and risk-outcome associations. METHODS: We used the CRA framework developed for previous iterations of GBD to estimate levels and trends in exposure, attributable deaths, and attributable disability-adjusted life-years (DALYs), by age group, sex, year, and location for 84 behavioural, environmental and occupational, and metabolic risks or groups of risks from 1990 to 2017. This study included 476 risk-outcome pairs that met the GBD study criteria for convincing or probable evidence of causation. We extracted relative risk and exposure estimates from 46 749 randomised controlled trials, cohort studies, household surveys, census data, satellite data, and other sources. We used statistical models to pool data, adjust for bias, and incorporate covariates. Using the counterfactual scenario of theoretical minimum risk exposure level (TMREL), we estimated the portion of deaths and DALYs that could be attributed to a given risk. We explored the relationship between development and risk exposure by modelling the relationship between the Socio-demographic Index (SDI) and risk-weighted exposure prevalence and estimated expected levels of exposure and risk-attributable burden by SDI. Finally, we explored temporal changes in risk-attributable DALYs by decomposing those changes into six main component drivers of change as follows: (1) population growth; (2) changes in population age structures; (3) changes in exposure to environmental and occupational risks; (4) changes in exposure to behavioural risks; (5) changes in exposure to metabolic risks; and (6) changes due to all other factors, approximated as the risk-deleted death and DALY rates, where the risk-deleted rate is the rate that would be observed had we reduced the exposure levels to the TMREL for all risk factors included in GBD 2017. FINDINGS: In 2017, 34·1 million (95% uncertainty interval [UI] 33·3-35·0) deaths and 1·21 billion (1·14-1·28) DALYs were attributable to GBD risk factors. Globally, 61·0% (59·6-62·4) of deaths and 48·3% (46·3-50·2) of DALYs were attributed to the GBD 2017 risk factors. When ranked by risk-attributable DALYs, high systolic blood pressure (SBP) was the leading risk factor, accounting for 10·4 million (9·39-11·5) deaths and 218 million (198-237) DALYs, followed by smoking (7·10 million [6·83-7·37] deaths and 182 million [173-193] DALYs), high fasting plasma glucose (6·53 million [5·23-8·23] deaths and 171 million [144-201] DALYs), high body-mass index (BMI; 4·72 million [2·99-6·70] deaths and 148 million [98·6-202] DALYs), and short gestation for birthweight (1·43 million [1·36-1·51] deaths and 139 million [131-147] DALYs). In total, risk-attributable DALYs declined by 4·9% (3·3-6·5) between 2007 and 2017. In the absence of demographic changes (ie, population growth and ageing), changes in risk exposure and risk-deleted DALYs would have led to a 23·5% decline in DALYs during that period. Conversely, in the absence of changes in risk exposure and risk-deleted DALYs, demographic changes would have led to an 18·6% increase in DALYs during that period. The ratios of observed risk exposure levels to exposure levels expected based on SDI (O/E ratios) increased globally for unsafe drinking water and household air pollution between 1990 and 2017. This result suggests that development is occurring more rapidly than are changes in the underlying risk structure in a population. Conversely, nearly universal declines in O/E ratios for smoking and alcohol use indicate that, for a given SDI, exposure to these risks is declining. In 2017, the leading Level 4 risk factor for age-standardised DALY rates was high SBP in four super-regions: central Europe, eastern Europe, and central Asia; north Africa and Middle East; south Asia; and southeast Asia, east Asia, and Oceania. The leading risk factor in the high-income super-region was smoking, in Latin America and Caribbean was high BMI, and in sub-Saharan Africa was unsafe sex. O/E ratios for unsafe sex in sub-Saharan Africa were notably high, and those for alcohol use in north Africa and the Middle East were notably low. INTERPRETATION: By quantifying levels and trends in exposures to risk factors and the resulting disease burden, this assessment offers insight into where past policy and programme efforts might have been successful and highlights current priorities for public health action. Decreases in behavioural, environmental, and occupational risks have largely offset the effects of population growth and ageing, in relation to trends in absolute burden. Conversely, the combination of increasing metabolic risks and population ageing will probably continue to drive the increasing trends in non-communicable diseases at the global level, which presents both a public health challenge and opportunity. We see considerable spatiotemporal heterogeneity in levels of risk exposure and risk-attributable burden. Although levels of development underlie some of this heterogeneity, O/E ratios show risks for which countries are overperforming or underperforming relative to their level of development. As such, these ratios provide a benchmarking tool to help to focus local decision making. Our findings reinforce the importance of both risk exposure monitoring and epidemiological research to assess causal connections between risks and health outcomes, and they highlight the usefulness of the GBD study in synthesising data to draw comprehensive and robust conclusions that help to inform good policy and strategic health planning. FUNDING: Bill & Melinda Gates Foundation.

TRAUMATIC BRAIN INJURY can often be associated with long-lasting symptoms and effects on function in a wide variety of areas. Expertise in the assessment and management of chronic physical, cognitive, and behavioral complaints is limited in many geographic areas, especially in rural America. Even in urban and suburban areas, the ability to fund treatment and education may be limited over the long course of recovery from and living with a chronic disorder. However, alternatives to face-to-face visits and therapy may be found through the blossoming of communication technologies. Few are without access to good reliable telephone services these days and, increasingly, Internet access is available through cable and wireless services. Audio and visual contact is possible with individuals and groups through various means. Facebook, Wikis, and Twitter, all new and innovative means of communication, are potentially available to extend the reach of the healthcare provider. Reaching out electronically to provide treatment and education to patients and caregivers is the focus of this issue of The Journal of Head Trauma Rehabilitation. Dr Bombardier and colleagues report on the results of a telephone-based counseling intervention aimed at educating and improving problem-solving skills of persons with moderate to severe traumatic brain injury with a range of depressive symptoms. Dr Wade and her group present their findings on using Web-based education and therapy to improve outcomes among children, adolescents, and their families. Finally, focusing on caregiver support and education, Dr Sander and her fellow investigators describe the use of videoconferencing technology to provide access to those living at a distance from the brain injury rehabilitation site. Many pilot research and clinical uses of Web-based communication technology can be found, particularly in the military (eg, www.afterdeployment.org) and veterans healthcare worlds. Little is currently known about how and who accesses these resources, how effective they are in terms of education and outcome, or how these electronic resources compare with more traditional avenues of education and treatment. Experience gained in other fields of healthcare will need to be evaluated in light of the special cognitive challenges our patients bring to the process, for both education and therapy. Definitions and measures of “dosing” for interventions delivered by telecommunication methods will require further explication. With respect to currently available funding, only face-to-face education and treatment are generally covered by insurers and healthcare intermediaries, funded by government. As these techniques are researched and further developed, the means of financing electronically mediated interventions will need to be resolved. We could not present these papers without stretching our own avenues of education and dissemination as well. We will be presenting a Webinar on this JHTR Telerehabilitation issue at 3 PM ET on August 6, 2009. Registration for the Webinar, part of the Mitch Rosenthal Memorial Lecture series, will be available in the bookstore of the Brain Injury Association of America in early July. The path is www.biausa.org. Click on Bookstore, and then click on Strauss and Rosenthal Lecture Series to register. More information can be obtained by contacting Marianna Abashian at [email protected]. Kathleen R. Bell, MD Associate Professor, Rehabilitation Medicine, University of Washington, Seattle (Bell) Tessa Hart, PhD Institute Scientist, Moss Rehabilitation Research Institute, Research Associate Professor, Jefferson Medical College, Philadelphia, Pennsylvania (Hart)

BACKGROUND: Chronic non-cancer pain, a disabling and distressing condition, is common in adults. It is a global public health problem and economic burden on health and social care systems and on people with chronic pain. Psychological treatments aim to reduce pain, disability and distress. This review updates and extends its previous version, published in 2012. OBJECTIVES: To determine the clinical efficacy and safety of psychological interventions for chronic pain in adults (age > 18 years) compared with active controls, or waiting list/treatment as usual (TAU). SEARCH METHODS: We identified randomised controlled trials (RCTs) of psychological therapies by searching CENTRAL, MEDLINE, Embase and PsycINFO to 16 April 2020. We also examined reference lists and trial registries, and searched for studies citing retrieved trials. SELECTION CRITERIA: RCTs of psychological treatments compared with active control or TAU of face-to-face therapies for adults with chronic pain. We excluded studies of headache or malignant disease, and those with fewer than 20 participants in any arm at treatment end. DATA COLLECTION AND ANALYSIS: Two or more authors rated risk of bias, extracted data, and judged quality of evidence (GRADE). We compared cognitive behavioural therapy (CBT), behavioural therapy (BT), and acceptance and commitment therapy (ACT) with active control or TAU at treatment end, and at six month to 12 month follow-up. We did not analyse the few trials of other psychological treatments. We assessed treatment effectiveness for pain intensity, disability, and distress. We extracted data on adverse events (AEs) associated with treatment. MAIN RESULTS: We added 41 studies (6255 participants) to 34 of the previous review's 42 studies, and now have 75 studies in total (9401 participants at treatment end). Most participants had fibromyalgia, chronic low back pain, rheumatoid arthritis, or mixed chronic pain. Most risk of bias domains were at high or unclear risk of bias, with selective reporting and treatment expectations mostly at unclear risk of bias. AEs were inadequately recorded and/or reported across studies. CBT The largest evidence base was for CBT (59 studies). CBT versus active control showed very small benefit at treatment end for pain (standardised mean difference (SMD) -0.09, 95% confidence interval (CI) -0.17 to -0.01; 3235 participants; 23 studies; moderate-quality evidence), disability (SMD -0.12, 95% CI -0.20 to -0.04; 2543 participants; 19 studies; moderate-quality evidence), and distress (SMD -0.09, 95% CI -0.18 to -0.00; 3297 participants; 24 studies; moderate-quality evidence). We found small benefits for CBT over TAU at treatment end for pain (SMD -0.22, 95% CI -0.33 to -0.10; 2572 participants; 29 studies; moderate-quality evidence), disability (SMD -0.32, 95% CI -0.45 to -0.19; 2524 participants; 28 studies; low-quality evidence), and distress (SMD -0.34, 95% CI -0.44 to -0.24; 2559 participants; 27 studies; moderate-quality evidence). Effects were largely maintained at follow-up for CBT versus TAU, but not for CBT versus active control. Evidence quality for CBT outcomes ranged from moderate to low. We rated evidence for AEs as very low quality for both comparisons. BT We analysed eight studies (647 participants). We found no evidence of difference between BT and active control at treatment end (pain SMD -0.67, 95% CI -2.54 to 1.20, very low-quality evidence; disability SMD -0.65, 95% CI -1.85 to 0.54, very low-quality evidence; or distress SMD -0.73, 95% CI -1.47 to 0.01, very low-quality evidence). At follow-up, effects were similar. We found no evidence of difference between BT and TAU (pain SMD -0.08, 95% CI -0.33 to 0.17, low-quality evidence; disability SMD -0.02, 95% CI -0.24 to 0.19, moderate-quality evidence; distress SMD 0.22, 95% CI -0.10 to 0.54, low-quality evidence) at treatment end. At follow-up, we found one to three studies with no evidence of difference between BT and TAU. We rated evidence for all BT versus active control outcomes as very low quality; for BT versus TAU. Evidence quality ranged from moderate to very low. We rated evidence for AEs as very low quality for BT versus active control. No studies of BT versus TAU reported AEs. ACT We analysed five studies (443 participants). There was no evidence of difference between ACT and active control for pain (SMD -0.54, 95% CI -1.20 to 0.11, very low-quality evidence), disability (SMD -1.51, 95% CI -3.05 to 0.03, very low-quality evidence) or distress (SMD -0.61, 95% CI -1.30 to 0.07, very low-quality evidence) at treatment end. At follow-up, there was no evidence of effect for pain or distress (both very low-quality evidence), but two studies showed a large benefit for reducing disability (SMD -2.56, 95% CI -4.22 to -0.89, very low-quality evidence). Two studies compared ACT to TAU at treatment end. Results should be interpreted with caution. We found large benefits of ACT for pain (SMD -0.83, 95% CI -1.57 to -0.09, very low-quality evidence), but none for disability (SMD -1.39, 95% CI -3.20 to 0.41, very low-quality evidence), or distress (SMD -1.16, 95% CI -2.51 to 0.20, very low-quality evidence). Lack of data precluded analysis at follow-up. We rated evidence quality for AEs to be very low. We encourage caution when interpreting very low-quality evidence because the estimates are uncertain and could be easily overturned. AUTHORS' CONCLUSIONS: We found sufficient evidence across a large evidence base (59 studies, over 5000 participants) that CBT has small or very small beneficial effects for reducing pain, disability, and distress in chronic pain, but we found insufficient evidence to assess AEs. Quality of evidence for CBT was mostly moderate, except for disability, which we rated as low quality. Further trials may provide more precise estimates of treatment effects, but to inform improvements, research should explore sources of variation in treatment effects. Evidence from trials of BT and ACT was of moderate to very low quality, so we are very uncertain about benefits or lack of benefits of these treatments for adults with chronic pain; other treatments were not analysed. These conclusions are similar to our 2012 review, apart from the separate analysis of ACT.

The ESC/ERS Guidelines represent the views of the ESC and ERS and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC and ERS are not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC/ERS Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC/ERS Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC/ERS Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC/ERS Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

OBJECTIVE: To update and expand the 2013 Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the ICU. DESIGN: Thirty-two international experts, four methodologists, and four critical illness survivors met virtually at least monthly. All section groups gathered face-to-face at annual Society of Critical Care Medicine congresses; virtual connections included those unable to attend. A formal conflict of interest policy was developed a priori and enforced throughout the process. Teleconferences and electronic discussions among subgroups and whole panel were part of the guidelines' development. A general content review was completed face-to-face by all panel members in January 2017. METHODS: Content experts, methodologists, and ICU survivors were represented in each of the five sections of the guidelines: Pain, Agitation/sedation, Delirium, Immobility (mobilization/rehabilitation), and Sleep (disruption). Each section created Population, Intervention, Comparison, and Outcome, and nonactionable, descriptive questions based on perceived clinical relevance. The guideline group then voted their ranking, and patients prioritized their importance. For each Population, Intervention, Comparison, and Outcome question, sections searched the best available evidence, determined its quality, and formulated recommendations as "strong," "conditional," or "good" practice statements based on Grading of Recommendations Assessment, Development and Evaluation principles. In addition, evidence gaps and clinical caveats were explicitly identified. RESULTS: The Pain, Agitation/Sedation, Delirium, Immobility (mobilization/rehabilitation), and Sleep (disruption) panel issued 37 recommendations (three strong and 34 conditional), two good practice statements, and 32 ungraded, nonactionable statements. Three questions from the patient-centered prioritized question list remained without recommendation. CONCLUSIONS: We found substantial agreement among a large, interdisciplinary cohort of international experts regarding evidence supporting recommendations, and the remaining literature gaps in the assessment, prevention, and treatment of Pain, Agitation/sedation, Delirium, Immobility (mobilization/rehabilitation), and Sleep (disruption) in critically ill adults. Highlighting this evidence and the research needs will improve Pain, Agitation/sedation, Delirium, Immobility (mobilization/rehabilitation), and Sleep (disruption) management and provide the foundation for improved outcomes and science in this vulnerable population.

The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

he ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and
\naccurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

BACKGROUND: Human resources for rehabilitation are often a neglected component of health services strengthening and health workforce development. This may be partly related to weaknesses in the available research and evidence to inform advocacy and programmatic strategies. The objective of this study was to quantitatively describe the global situation in terms of supply of and need for human resources for health-related rehabilitation services, as a basis for strategy development of the workforce in physical and rehabilitation medicine. METHODS: Data for assessing supply of and need for rehabilitative personnel were extracted and analyzed from statistical databases maintained by the World Health Organization and other national and international health information sources. Standardized classifications were used to enhance cross-national comparability of findings. RESULTS: Large differences were found across countries and regions between assessed need for services requiring health workers associated to physical and rehabilitation medicine against estimated supply of health personnel skilled in rehabilitation services. Despite greater need, low- and middle-income countries tended to report less availability of skilled health personnel, although the strength of the supply-need relationship varied across geographical and economic country groupings. CONCLUSION: The evidence base on human resources for health-related rehabilitation services remains fragmented, the result of limited availability and use of quality, comparable data and information within and across countries. This assessment offered the first global baseline, intended to catalyze further research that can be translated into evidence to support human resources for rehabilitation policy and practice.

This is the third paper of the set recording the results of the suite of tests of general relativity (GR) performed on the signals from the fourth Gravitational-Wave Transient Catalog (GWTC-4.0), where we focus on the remnants of the binary mergers. We examine for the first time 42 events from the first part of the fourth observing run of the LIGO-Virgo-KAGRA detectors, alongside events from the previous observation runs, restricting our analysis to the confident signals, which were measured in at least two detectors and that have false alarm rates $\le 10^{-3} \mathrm{yr}^{-1}$. This paper focuses on seven tests of the coalescence remnants. Three of these are tests of the ringdown and its consistency with the expected quasinormal mode spectrum of a Kerr black hole. Specifically, two tests analyze just the ringdown in the time domain, and the third test analyzes the entire signal in the frequency domain. Four tests allow for the existence of possible echoes arriving after the end of the ringdown, which are not expected in GR. We find overall consistency of the remnants with GR. When combining events by multiplying likelihoods (hierarchically), one analysis finds that the GR predict

Medical Journals play an important role in the diffusion of knowledge. Medical Hydrology Journals are not an exception. In this communication we analyze what is the state of the communication of knowledge in Health Resort Medicine. We will organize the work in two parts: first, with the analysis of the specific Medical Hydrology journals, which according to the repositories and antiquity are: Voprosy kurortologii, fizioterapii, i lechebnoĭ fizicheskoĭ kultury (Russia); La Presse thermale et climatique (France); Boletin de la Sociedad Espanola de Hidrologia Medica (Spain); La Clinica Termale (Italy); Balneo Research Journal (Romania); The Journal of The Japanese Society of Balneology, Climatology and Physical Medicine (Japan) and Acta Balneologica (Poland). And second, with the search of the publications written by Health Resort Medicine researchers (ISMH). For this we have used the bibliographic repositories PubMed, Scopus and Journal Citation Reports in the last five years and by order of mayor to minor score: International Journal of Biometeorology; Applied Clay Science, Rheumatology International; Israel Medical Association Journal; Journal of Environmental Protection and Ecology; PM & R: the journal of injury, function, and rehabilitation; Gaceta Sanitaria; Annals of Physical and Rehabilitation Medicine; Clinical Rheumatology; European Journal of Physical and Rehabilitation Medicine; Bulletin de l'Academie Nationale de Medecine; European Journal of Integrative Medicine; Nutricion Hospitalaria; Revue du Rhumatisme Monographies; As well as twenty-two publications with a single article such as Advances in Clinical and Experimental Medicine; American Journal of Physical Medicine and Rehabilitation; Annals of the Rheumatic Diseases; British Journal of Cancer; European Journal of Cancer; Evidence-based Complementary and Alternative Medicine; Vasa - European Journal of Vascular Medicine, etc.

The international collaboration designing and constructing the Deep Underground Neutrino Experiment (DUNE) at the Long-Baseline Neutrino Facility (LBNF) has developed a two-phase strategy toward the implementation of this leading-edge, large-scale science project. The ambitious physics program of Phase I and Phase II of DUNE is dependent upon deployment and utilization of significant computing resources, and successful research and development of software (both infrastructure and algorithmic) in order to achieve these scientific goals. This submission discusses the computing resources projections, infrastructure support, and software development needed for DUNE during the coming decades as an input to the European Strategy for Particle Physics Update for 2026. The DUNE collaboration is submitting four main contributions to the 2026 Update of the European Strategy for Particle Physics process. This submission to the 'Computing' stream focuses on DUNE software and computing. Additional inputs related to the DUNE science program, DUNE detector technologies and R&D, and European contributions to Fermilab accelerator upgrades and facilities for the DUNE experiment, are also being su

The worldwide LIGO-Virgo-KAGRA network of gravitational-wave (GW) detectors continues to increase in sensitivity, thus increasing the quantity and quality of the detected GW signals from compact binary coalescences. These signals allow us to perform ever-more sensitive tests of general relativity (GR) in the dynamical and strong-field regime of gravity. This paper is the first of three, where we present the results of a suite of tests of GR using the binary signals included in the fourth GW Transient Catalog (GWTC-4.0), i.e., up to and including the first part of the fourth observing run of the detectors (O4a). We restrict our analysis to the 91 confident signals, henceforth called events, that were measured by at least two detectors, and have false alarm rates $\le 10^{-3} \mathrm{yr}^{-1}$. These include 42 events from O4a. This first paper presents an overview of the methods, selection of events and GR tests, and serves as a guidemap for all three papers. Here we focus on the four general tests of consistency, where we find no evidence for deviations from our models. Specifically, for all the events considered, we find consistency of the residuals with noise. The final mass and

The discovery of joint sources of high-energy neutrinos and gravitational waves has been a primary target for the LIGO, Virgo, KAGRA, and IceCube observatories. The joint detection of high-energy neutrinos and gravitational waves would provide insight into cosmic processes, from the dynamics of compact object mergers and stellar collapses to the mechanisms driving relativistic outflows. The joint detection of multiple cosmic messengers can also elevate the significance of the common observation even when some or all of the constituent messengers are sub-threshold, i.e. not significant enough to declare their detection individually. Using data from the LIGO, Virgo, and IceCube observatories, including sub-threshold events, we searched for common sources of gravitational waves and high-energy neutrinos during the third observing run of Advanced LIGO and Advanced Virgo detectors. Our search did not identify significant joint sources. We derive constraints on the rate densities of joint sources. Our results constrain the isotropic neutrino emission from gravitational-wave sources for very high values of the total energy emitted in neutrinos (> $10^{52} - 10^{54}$ erg).

A measurement of the $CP$-violating observables from $B^{\pm}\rightarrow D^* K^{\pm}$ and $B^{\pm}\rightarrow D^* π^{\pm}$ decays is presented, where $D^* (D) $ is an admixture of $D^{*0}$ and $\bar{D}^{*0}$ ($D^0$ and $\bar{D}^0$) states and is reconstructed through the decay chains $ D^* \rightarrow Dπ^0/γ$ and $D \to K_S^0 π^+π^-/K_S^0 K^+K^-$. The measurement is performed by analysing the signal yield variation across the $D$ decay phase space and is independent of any amplitude model. The data sample used was collected by the LHCb experiment in proton-proton collisions and corresponds to a total integrated luminosity of 9 fb$^{-1}$ at centre-of-mass energies of 7, 8 and 13 TeV. The CKM angle $γ$ is determined to be $(69^{+13}_{-14})^{\circ}$ using the measured $CP$-violating observables. The hadronic parameters $r^{D^* K^{\pm}}_B, r^{D^* π^{\pm}}_B, δ^{D^* K^{\pm}}_B, δ^{D^* π^{\pm}}_B$, which are the ratios and strong phase differences between favoured and suppressed $B^{\pm}$ decays, are also reported.

BACKGROUND: The Danish National Patient Registry (DNPR) is one of the world's oldest nationwide hospital registries and is used extensively for research. Many studies have validated algorithms for identifying health events in the DNPR, but the reports are fragmented and no overview exists. OBJECTIVES: To review the content, data quality, and research potential of the DNPR. METHODS: We examined the setting, history, aims, content, and classification systems of the DNPR. We searched PubMed and the Danish Medical Journal to create a bibliography of validation studies. We included also studies that were referenced in retrieved papers or known to us beforehand. Methodological considerations related to DNPR data were reviewed. RESULTS: During 1977-2012, the DNPR registered 8,085,603 persons, accounting for 7,268,857 inpatient, 5,953,405 outpatient, and 5,097,300 emergency department contacts. The DNPR provides nationwide longitudinal registration of detailed administrative and clinical data. It has recorded information on all patients discharged from Danish nonpsychiatric hospitals since 1977 and on psychiatric inpatients and emergency department and outpatient specialty clinic contacts since 1995. For each patient contact, one primary and optional secondary diagnoses are recorded according to the International Classification of Diseases. The DNPR provides a data source to identify diseases, examinations, certain in-hospital medical treatments, and surgical procedures. Long-term temporal trends in hospitalization and treatment rates can be studied. The positive predictive values of diseases and treatments vary widely (<15%-100%). The DNPR data are linkable at the patient level with data from other Danish administrative registries, clinical registries, randomized controlled trials, population surveys, and epidemiologic field studies - enabling researchers to reconstruct individual life and health trajectories for an entire population. CONCLUSION: The DNPR is a valuable tool for epidemiological research. However, both its strengths and limitations must be considered when interpreting research results, and continuous validation of its clinical data is essential.

The Gravitational-Wave Transient Catalog (GWTC) is a collection of short-duration (transient) gravitational wave signals identified by the LIGO-Virgo-KAGRA Collaboration in gravitational-wave data produced by the eponymous detectors. The catalog provides information about the identified candidates, such as the arrival time and amplitude of the signal and properties of the signal's source as inferred from the observational data. GWTC is the data release of this dataset and version 4.0 extends the catalog to include observations made during the first part of the fourth LIGO-Virgo-KAGRA observing run up until 2024 January 31. This paper marks an introduction to a collection of articles related to this version of the catalog, GWTC-4.0. The collection of articles accompanying the catalog provides documentation of the methods used to analyze the data, summaries of the catalog of events, observational measurements drawn from the population, and detailed discussions of selected candidates

The first search for the $B_s^0\rightarrow K^-π^+γ$ decay in the range $796&lt;m(K^-π^+)&lt;1800\,\text{MeV/}c^2$ is performed using data from proton-proton collisions collected by the LHCb experiment at centre-of-mass energies of 7, 8, and 13 TeV, corresponding to an integrated luminosity of 9 fb$^{-1}$. The photons are reconstructed through their conversion into an electron-positron pair, which significantly improves the mass resolution of the reconstructed decays with respect to decays with an unconverted photon. A signal excess with a significance of 3.5 standard deviations is measured, constituting the first experimental evidence for this decay. In the range $796&lt;m(K^-π^+)&lt;996\,\text{MeV/}c^2$, the ratio ${\cal R}$ between the branching fractions of the signal decay and the favoured $\kern 0.18em\overline{\kern -0.18em B}{}^0\rightarrow K^- π^+γ$ decay is measured to be ${\cal R} = (3.7\pm1.2\pm0.4)\times10^{-2}$ where the first uncertainty is statistical and the second is systematic. This measurement is consistent with the value predicted in the Standard Model. In the range $996&lt;m(K^-π^+)&lt;1800\,\text{MeV/}c^2$, the ratio ${\cal R} = (0.2\pm2.7\pm1.3)\times10^{-2}$

The gravitational-wave signal GW250114 was observed by the two LIGO detectors with a network matched-filter signal-to-noise ratio of 80. The signal was emitted by the coalescence of two black holes with near-equal masses $m_1 = 33.6^{+1.2}_{-0.8}\,M_\odot$ and $m_2 = 32.2^{+0.8}_{-1.3}\,M_\odot$, and small spins $χ_{1,2} \leq 0.26$ (90% credibility) and negligible eccentricity $e \leq 0.03$. Post-merger data excluding the peak region are consistent with the dominant quadrupolar $(\ell = |m| = 2)$ mode of a Kerr black hole and its first overtone. We constrain the modes' frequencies to $\pm 30\%$ of the Kerr spectrum, providing a test of the remnant's Kerr nature. We also examine Hawking's area law, also known as the second law of black hole mechanics, which states that the total area of the black hole event horizons cannot decrease with time. A range of analyses that exclude up to 5 of the strongest merger cycles confirm that the remnant area is larger than the sum of the initial areas to high credibility.